Skip to main content
. 2004 Jul 10;54(2):172–178. doi: 10.1007/s00262-004-0575-z

Table 3.

HLA-CLys80 and HLA-CAsn80 group KIR ligands in melanoma patients and healthy controls

Ligands Frequency
Patients (n=50) Controls (n=54)
HLA-CAsn80 18 (36.0%) 16 (29.63%)
HLA-CLys80 6 (12.0%)* 17 (31.48%)
HLA-CLys80;Asn80 26 (52.0%) 21 (38.89%)

*p=0.017; OR=0.270; 95% CI, 0.09–0.91